MaxCyte, Inc. Declaration of Audit Remuneration (6267T)
16 October 2017 - 5:00PM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 6267T
MaxCyte, Inc.
16 October 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
Declaration of Audit Remuneration
Maryland, USA - 16 October 2017: MaxCyte (LSE: MXCT, MXCR), in
order to assist investors in considering the resolutions proposed
ahead of its 2017 AGM, notes that the remuneration of the Company's
auditors, Aronson LLC, for the financial year ended 2016 for
audit-related services amounted to approximately $82,000 plus
approximately $10,000 for non-audit related services.
The Annual General Meeting of Stockholders is planned to be held
at 11 a.m. GMT on 31 October 2017 at InterContinental London Park
Lane, One Hamilton Place, Park Lane, London W1J 7QY, United
Kingdom.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Duncan Monteith
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Lindsey Neville
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving
the acceleration of the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
platform to biopharmaceutical partners engaged in drug discovery
and development, biomanufacturing, and cell therapy, including gene
editing and immuno-oncology. With its robust delivery platform,
MaxCyte's team of scientific experts helps its partners to unlock
their product potential and solve problems. This platform allows
for the engineering of nearly all cell types, including human
primary cells, with any molecule, at any scale. It also provides a
high degree of consistency and minimal cell disturbance, thereby
facilitating rapid, large-scale, clinical and commercial grade cell
engineering in a non-viral system and with low-toxicity concerns.
The Company's cell-engineering platform is FDA-accredited,
providing MaxCyte's customers and partners with an established
regulatory path to commercialize cell-based medicines. MaxCyte is
also developing CARMA, its proprietary, breakthrough platform in
immuno-oncology, to rapidly manufacture CAR therapies for a broad
range of cancer indications, including solid tumours where existing
CAR-T approaches face
significant challenges. For more information, visit http://www.maxcyte.com/.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDBBDGISBBGRU
(END) Dow Jones Newswires
October 16, 2017 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024